Baker Bros. Advisors LP Ovid Therapeutics Inc. Transaction History

Baker Bros. Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.42 - $4.47 $2.31 Million - $4.27 Million	-955,690 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.28 - $6.84 $832,038 - $2.5 Million	364,929 Added 61.77%	955,690 $2.21 Million
Q3 2020 Nov 16, 2020	BUY	$5.39 - $8.24 $714,218 - $1.09 Million	132,508 Added 28.92%	590,761 $3.39 Million
Q2 2020 Aug 14, 2020	BUY	$2.67 - $7.91 $1.04 Million - $3.08 Million	388,782 Added 559.63%	458,253 $3.38 Million
Q1 2020 May 15, 2020	BUY	$2.03 - $4.35 $141,026 - $302,198	69,471 New	69,471 $207,000
Q4 2018 Feb 13, 2019	SELL	$2.42 - $6.6 $537,576 - $1.47 Million	-222,139 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$5.6 - $11.0 $143,326 - $281,534	-25,594 Reduced 10.33%	222,139 $1.26 Million
Q1 2018 May 15, 2018	SELL	$6.53 - $9.82 $558,968 - $840,592	-85,600 Reduced 25.68%	247,733 $1.75 Million
Q3 2017 Nov 14, 2017	BUY	$5.32 - $9.77 $1.77 Million - $3.26 Million	333,333	333,333 $2.86 Million

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $73.9M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.